-
公开(公告)号：US20240246909A1
公开(公告)日：2024-07-25
申请号：US18408389
申请日：2024-01-09
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
CPC分类号： C07D209/08 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , A61P31/20 , A61P35/00 , C07D277/62 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D417/10 , C07D417/12 , C07D471/04 , C07D471/08 , C07D471/10 , C07D487/04 , C07D487/08 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号：US20200181078A1
公开(公告)日：2020-06-11
申请号：US16519590
申请日：2019-07-23
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
IPC分类号： C07D207/327 , C07D401/10 , C07D401/04 , C07D333/54 , C07D307/79 , C07D277/30 , C07D249/06 , C07D231/12 , C07D215/14 , C07D213/74 , C07D213/64 , C07D211/70 , C07D207/16 , C07D207/14 , C07D207/12 , C07D207/08 , C07C317/44 , C07C229/64 , C07C65/28 , C07C65/19 , C07C63/66 , C07C53/18 , C07D213/55 , C07D295/155 , C07D209/08 , C07D487/04 , C07D471/04 , C07D417/10 , C07D409/10 , C07D239/26 , C07D403/10 , C07D235/06 , C07C317/14 , C07C311/17 , C07C311/16 , C07C311/08 , C07C235/58 , C07C233/65 , C07C233/64 , C07C233/11 , C07C217/84 , C07C211/27 , C07C255/55 , C07C255/54 , C07C229/56 , A61K31/44 , A61K31/192 , A61K31/496 , A61K31/4439 , A61K31/404
摘要： Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
-
公开(公告)号：US10442763B2
公开(公告)日：2019-10-15
申请号：US15571223
申请日：2016-05-14
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , C07D403/12 , C07D405/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D471/08 , C07D487/08 , A61P35/00 , A61P31/20 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , C07D277/62 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D417/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
4.发明申请Methods and Compositions for Re-activating Epstein-Barr Virus and Screening Compounds Therefor 审中-公开重新激活爱泼斯坦 - 巴尔病毒和筛选化合物的方法和组合物公开(公告)号：US20160206601A1
公开(公告)日：2016-07-21
申请号：US14912949
申请日：2014-08-29
IPC分类号： A61K31/437 , C12Q1/02 , A61K31/69 , A61K31/522 , A61K45/06 , A61K31/19
CPC分类号： A61K31/437 , A61K31/19 , A61K31/522 , A61K31/69 , A61K45/06 , C07D471/04 , C12Q1/025 , A61K2300/00
摘要： In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided. (Formula I)
摘要翻译： 为了发现用于治疗由EBV引起的疾病的疗法，发现了用于鉴定重新激活EBV潜伏感染的化合物和基于四氢咔啉骨架的小分子家族的新型筛选试验。 具体地，化合物具有式（I）的结构，其中R1-R11在本文中定义，并激活/重新激活患者中各种细胞类型的EBV，因此可用于预防或治疗EBV阳性癌症， 任选地具有抗病毒剂。 在筛选这些化合物时，提供新的组合物，EBV阳性细胞系和方法。 （式I）
-
公开(公告)号：US10981867B2
公开(公告)日：2021-04-20
申请号：US16571896
申请日：2019-09-16
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Marianne Carlsen , Shuai Chen
IPC分类号： C07D209/08 , C07D403/12 , C07D405/14 , C07D401/12 , C07D405/12 , C07D409/12 , C07D487/08 , C07D471/08 , C07D417/12 , A61P35/00 , A61P31/20 , A61K31/404 , A61K31/41 , A61K31/4155 , A61K31/422 , A61K31/426 , A61K31/427 , A61K31/433 , A61K31/435 , A61K31/437 , A61K31/4375 , A61K31/4439 , A61K31/454 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/541 , A61K31/551 , A61K45/06 , C07D277/62 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D417/10 , C07D471/04 , C07D471/10 , C07D487/04 , C07D491/107
摘要： The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
6.发明申请公开(公告)号：US20190240202A1
公开(公告)日：2019-08-08
申请号：US16386473
申请日：2019-04-17
IPC分类号： A61K31/437 , C12Q1/02 , A61K45/06 , A61K31/19 , A61K31/69 , A61K31/522 , C07D471/04
CPC分类号： A61K31/437 , A61K31/19 , A61K31/522 , A61K31/69 , A61K45/06 , C07D471/04 , C12Q1/025 , A61K2300/00
摘要： In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided.
-
公开(公告)号：US09856214B2
公开(公告)日：2018-01-02
申请号：US15036211
申请日：2014-11-14
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
IPC分类号： A61K31/405 , A61K31/41 , A61K31/42 , C07D209/42 , C07D401/00 , C07D403/00 , C07D207/327 , C07C229/56 , C07C255/54 , C07C255/55 , C07C211/27 , C07C217/84 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07D235/06 , C07D403/10 , C07D239/26 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D209/08 , C07D295/155 , C07D213/55 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C229/64 , C07C317/44 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/70 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D249/06 , C07D277/30 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10
CPC分类号： C07D207/327 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C211/27 , C07C217/84 , C07C229/56 , C07C229/64 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C255/54 , C07C255/55 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07C317/44 , C07C2601/02 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D209/08 , C07D211/70 , C07D213/55 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D235/06 , C07D239/26 , C07D249/06 , C07D277/30 , C07D295/155 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10 , C07D403/10 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04
摘要： The invention provides EBNA1 inhibitors, and pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The compounds and compositions of the invention are further useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. The compounds and compositions of the invention are further useful for the treatment of diseases caused by lytic EBV infection.
-
公开(公告)号：US11242338B2
公开(公告)日：2022-02-08
申请号：US16414198
申请日：2019-05-16
申请人： THE WISTAR INSTITUTE
IPC分类号： A61K45/06 , A61K31/404 , A61P31/22 , A61P35/02 , A61P25/28 , C07D405/12 , A61K9/00
摘要： The invention relates, in certain aspects, to developable forms of certain compounds that are useful to treat and/or prevent EBV infection and related conditions in a subject. The invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
-
公开(公告)号：US10421718B2
公开(公告)日：2019-09-24
申请号：US15814600
申请日：2017-11-16
发明人： Troy E. Messick , Garry R. Smith , Allen B. Reitz , Paul M. Lieberman , Mark E. McDonnell , Yan Zhang , Venkata Velvadapu
IPC分类号： A61K31/195 , A61K31/405 , A61K31/41 , A61K31/42 , A61K31/415 , A61K31/40 , C07D207/327 , A61K31/404 , A61K31/4439 , A61K31/496 , A61K31/192 , A61K31/44 , C07C229/56 , C07C255/54 , C07C255/55 , C07C211/27 , C07C217/84 , C07C233/11 , C07C233/64 , C07C233/65 , C07C235/58 , C07C311/08 , C07C311/16 , C07C311/17 , C07C317/14 , C07D235/06 , C07D403/10 , C07D239/26 , C07D409/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D209/08 , C07D295/155 , C07D213/55 , C07C53/18 , C07C63/66 , C07C65/19 , C07C65/28 , C07C229/64 , C07C317/44 , C07D207/08 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/70 , C07D213/64 , C07D213/74 , C07D215/14 , C07D231/12 , C07D249/06 , C07D277/30 , C07D307/79 , C07D333/54 , C07D401/04 , C07D401/10
摘要： Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
-
10.发明授权公开(公告)号：US10307406B2
公开(公告)日：2019-06-04
申请号：US14912949
申请日：2014-08-29
IPC分类号： A61K31/437 , C07D471/04 , A61K31/19 , A61K31/522 , A61K31/69 , A61K45/06 , C12Q1/02
摘要： In an effort to discover therapies for treating diseases caused by EBV, a novel screening assay for identifying compounds that reactivate EBV latent infection and a family of small molecules based on a tetrahydrocarboline backbone were discovered. Specifically, the compounds have the structure of the formula (I), wherein R1-R11 are defined herein and activate/reactivate EBV in a variety of cell types in a patient and are, therefore, useful in preventing or treating EBV-positive cancer, optionally with an anti-viral agent. In screening these compounds, novel compositions, EBV-positive cell lines, and methods are provided. (Formula I)
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.024 秒)
